Notably, Notch inhibitors, PI3K/AKT inhibitors, and STAT3 inhibitors emerge as frequent therapeutic targets, underscoring their pivotal roles in glioma pathogenesis and promising avenues for intervention. Here, AKT1 is linked to glioma.